In the current study, we evaluated the MTA1-targeted efficacy of pterostilbene in autochthonous prostate cancer pre-clinical models that harbor prostate-specific Pten heterozygous (Pb-Cre4; Pten+/f, hereafter referred as Pten+/f) and Pten knockout (Pb-Cre4; Ptenf/f, hereafter referred as Ptenf/f), which represent chemoprevention and intervention scenarios, respectively. The gene discussed is MTA1; the disease is Familial prostate cancer.